News Quantified

CAPR – capricor therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at UBS Group AG.

Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.

Capricor: A Detailed Examination Of Hope-3 [Seeking Alpha]

Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.

11.9%

IN-LINE

-0.1%

MISS

1.1%

MISS

15.6%

BEAT

Oppenheimer Holdings, Inc.

Form 424B5 CAPRICOR THERAPEUTICS,

Form 8-K CAPRICOR THERAPEUTICS, For: Dec 05

Form 424B3 CAPRICOR THERAPEUTICS,

Form 424B5 CAPRICOR THERAPEUTICS,

Form 10-Q CAPRICOR THERAPEUTICS, For: Sep 30

Top News Gainers

4/29 New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002 251.2%

7/15 Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy 94.1%

3/24 Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development 49.2%

3/24 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 21.7%

9/17 Capricor Therapeutics (CAPR) Presents At 21st Annual H.C. Wainwright Global Investment Conference - Slideshow [Seeking Alpha] 19.3%

3/17 Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion 15.8%

4/30 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 12.0%

9/6 Capricor Therapeutics to Present at Upcoming Conferences 10.3%

10/15 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.1%

12/27 Form SC 13G CAPRICOR THERAPEUTICS, Filed by: ARMISTICE CAPITAL, LLC 9.5%

Top News Decliners

4/3 Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy -37.5%

7/15 Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at HC Wainwright from $3.50 to $12.40. They now have a "buy" rating on the stock. -22.1%

7/25 Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy -16.6%

12/13 Form S-1/A CAPRICOR THERAPEUTICS, -16.0%

10/7 Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months -15.9%

7/22 Form 8-K CAPRICOR THERAPEUTICS, For: Jul 22 -13.0%

11/7 Q3/2019 9/30/2019 EPS -0.430 ZacksConsensus -0.700 ActVsEst 0.270 - Beat -12.4%

12/13 Form S-1/A CAPRICOR THERAPEUTICS, -11.9%

7/16 Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.9%

7/17 Form S-3/A CAPRICOR THERAPEUTICS, -10.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day